program
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Expected Milestones Planned Next Steps
INVELTYS®: First BID corticosteroid indicated for the treatment of post-operative ocular inflammation and pain
  • FDA approved on August 22, 2018
  • US launch in January 2019
EYSUVIS
(KPI-121 0.25%) for temporary relief of the signs and symptoms of dry eye disease
  • Positive STRIDE 3 topline results announced in Q1 2020
  • PDUFA goal date of October 30, 2020
KPI-285: rTKI for Retinal Diseases
  • Complete evaluation of our lead compound, KPI-285, for retinal disease
Novel next-generation anti-inflammatories
  • Select lead compounds
program
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Expected Milestones Planned Next Steps
INVELTYS®: First BID corticosteroid indicated for the treatment of post-operative ocular inflammation and pain
  • FDA approved on August 22, 2018
  • US launch in January 2019
EYSUVIS
(KPI-121 0.25%) for temporary relief of the signs and symptoms of dry eye disease
  • Positive STRIDE 3 topline results announced in Q1 2020
  • PDUFA goal date of October 30, 2020
KPI-285: rTKI for Retinal Diseases
  • Complete evaluation of our lead compound, KPI-285, for retinal disease
Novel next-generation anti-inflammatories
  • Select lead compounds

Please review our Privacy Statement. This website uses cookies. By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Statement.